Free same-day US shipping on orders over $150.00 · bulk pricing on 2+ vials
Kairo Labs
Shop
For research use only. Not for human or animal consumption.
Compound explainer

TB-500 (Thymosin β4 Fragment): Mechanism

TB-500 is a synthetic peptide studied in tissue-repair and cell-migration research, related to thymosin β4 (Tβ4), a naturally occurring 43-amino-acid actin-binding protein. The name TB-500 is frequently used interchangeably with thymosin β4 in the research supply context, but the two are not strictly identical, and understanding the distinction — and the central role of actin binding — is key to reading the literature correctly. This overview covers the mechanism, the TB-500 versus thymosin β4 clarification, and molecular framing as a reference-material explainer for research use only.

TB-500 vs thymosin β4: the clarification

Thymosin β4 is a native 43-residue peptide whose best-characterized property is binding to G-actin (monomeric actin) and regulating actin polymerization. The designation TB-500 is used in the research-supply space to refer to a thymosin β4-related peptide; depending on the source, TB-500 is described either as full-length synthetic thymosin β4 or as a synthetic fragment centered on the molecule's key active region.

The important active region is the actin-binding domain, and a central, highly conserved motif associated with actin binding is the sequence LKKTETQ. Because usage varies, a rigorous laboratory confirms exactly which sequence a given TB-500 lot contains via its Certificate of Analysis rather than assuming — the COA's sequence, mass, and purity data define what is actually in the vial.

  • Thymosin β4: native 43-amino-acid actin-binding peptide.
  • TB-500: a thymosin β4-related synthetic peptide (full-length or fragment, depending on source).
  • Key conserved actin-binding motif: LKKTETQ.
  • Always confirm the exact sequence supplied via the lot COA.

Actin binding — the core mechanism

The defining, most-studied mechanism of thymosin β4 and its fragments is interaction with actin. Thymosin β4 is the principal G-actin-sequestering peptide in many cell types: it binds monomeric actin and thereby helps regulate the balance between monomeric (G) and filamentous (F) actin, a balance central to the cytoskeletal dynamics that underlie cell migration, motility, and tissue-repair processes.

In cellular and animal models the literature studies how this actin regulation relates to cell migration and repair-associated signaling, along with associated effects on angiogenesis. These are mechanistic findings in research systems describing the molecule's cytoskeletal biology, not claims about effects in humans.

  • Binds monomeric G-actin (actin sequestration).
  • Helps regulate the G-actin / F-actin balance.
  • Actin dynamics underlie cell migration and motility studied in models.
  • Associated cell-migration and angiogenesis signaling investigated preclinically.

The Ac-SDKP fragment

Thymosin β4 contains, at its N-terminus, the tetrapeptide sequence Ac-Ser-Asp-Lys-Pro, known as Ac-SDKP (acetyl-N-Ser-Asp-Lys-Pro, also called seraspenide). Ac-SDKP is a naturally occurring fragment liberated from thymosin β4 and is itself a subject of research, studied in the literature in relation to angiogenesis and anti-fibrotic signaling in models.

This is relevant framing for TB-500 because it illustrates that thymosin β4 is a source of biologically studied fragments, and that TB-500-type materials are best understood as thymosin β4-derived peptides whose precise composition should be read from the COA.

  • Ac-SDKP (Ac-Ser-Asp-Lys-Pro, seraspenide): N-terminal tetrapeptide of thymosin β4.
  • A naturally liberated thymosin β4 fragment studied in its own right.
  • Investigated for angiogenesis and anti-fibrotic signaling in models.
  • Illustrates thymosin β4 as a source of studied active fragments.

BPC-157 vs TB-500

TB-500 is often studied alongside BPC-157 in tissue-repair research contexts, and the two are offered together as a research blend. They are mechanistically distinct: TB-500 acts through the thymosin β4 actin-binding system and cell-migration dynamics, while BPC-157 is a partial sequence of body protection compound associated with angiogenic and cytoprotective signaling.

The dedicated comparison page develops these mechanistic differences and how the literature co-studies them.

  • TB-500: thymosin β4-related, actin-binding and cell-migration mechanisms.
  • BPC-157: body-protection-compound fragment, angiogenic/cytoprotective signaling.
  • Mechanistically distinct; offered together as a research blend.

What the literature investigates

Research on thymosin β4 and TB-500 characterizes actin binding, cell-migration and motility effects, angiogenesis, and tissue-repair-associated signaling in cellular and animal models, along with the physicochemical properties of the synthetic peptide. As a reference material it is used to probe actin-regulatory biology and in tissue-repair comparator studies.

This work is laboratory and preclinical. Kairo Labs supplies TB-500 as a research reference compound for research use only; it is not for human or animal consumption, and nothing here is a health or therapeutic claim or any dosing guidance.

Verification and quality

Because TB-500 usage spans full-length and fragment forms, lot-level verification is especially important: a Certificate of Analysis reporting HPLC purity with its chromatogram, mass-spec identity comparing observed against theoretical mass, and the exact sequence and net peptide content tells you precisely which thymosin β4-related peptide the vial contains. Kairo Labs verifies to the lot — every batch is tested and its data retrievable.

See the COA guide for reading those measurements and the handling guides for reconstitution, storage, and stability.

Frequently asked
Is TB-500 the same as thymosin β4?

Not strictly. Thymosin β4 is the native 43-amino-acid actin-binding peptide; TB-500 is a thymosin β4-related synthetic peptide that, depending on the source, is described as either full-length synthetic thymosin β4 or a synthetic fragment centered on its key active region. Confirm the exact sequence supplied via the lot COA.

What is TB-500's core mechanism?

Its defining, most-studied mechanism is actin binding. Thymosin β4 is a principal G-actin-sequestering peptide that helps regulate the balance between monomeric and filamentous actin, a balance central to the cytoskeletal dynamics underlying cell migration and tissue-repair processes studied in models.

What is Ac-SDKP?

Ac-SDKP (acetyl-Ser-Asp-Lys-Pro, also called seraspenide) is the N-terminal tetrapeptide of thymosin β4, a naturally liberated fragment studied in its own right in relation to angiogenesis and anti-fibrotic signaling in models. It illustrates that thymosin β4 is a source of biologically studied fragments.

How does TB-500 differ from BPC-157?

TB-500 acts through the thymosin β4 actin-binding system and cell-migration dynamics, while BPC-157 is a partial sequence of body protection compound associated with angiogenic and cytoprotective signaling. They are mechanistically distinct but are sometimes co-studied and offered as a research blend.

Is TB-500 available for any human or animal use?

No. TB-500 is supplied strictly as a research reference material for research use only. It is not for human or animal consumption, and this page covers only mechanism, the thymosin β4 relationship, and molecular framing — no therapeutic claims or dosing.

Research Use Only. All products and information referenced by Kairo Labs are intended strictly for laboratory research and educational purposes. They are not for human or animal consumption, and not for diagnostic, therapeutic, or clinical use. This content describes mechanisms, molecular properties, and handling as studied in the scientific literature; it is educational, not medical advice, and not a recommendation to use any compound in humans or animals. Researchers are responsible for handling all materials in accordance with applicable laws, regulations, and institutional safety protocols.